It provides mechanistic interpretations for all principal aspects of AD and AACD, including the protective effect of Icelandic AβPP mutation, the early onset of FAD and the temporally sequential manifestation of AD in defined regions of the affected brain, and explains mechanisms underlying the observed effect of lecanemab and donanemab at the early symptomatic stage of AD. Here, APP is linked to Alzheimer disease.